 Happy New Year everybody. Welcome back to Investor and Tell. I'm Peter Clausi. Today we're talking to my old friend Thomas Smink from Hemostemics, HEM on the Venture Exchange. Hi, Tom. Happy New Year, Peter. Good to see you. Nice to see you again. You were absent for a little while and your absence was noted on a variety of bulletin boards. Welcome back. What happened? Thank you very much. We've been head down busy working on bringing Hemostemics back into commercial form. The main target of Hemostemics is to prevent the loss of limbs. And the treatment of your heart following a heart attack. I know you've got all the technical details. You've been loading up the board and the advisory board with very qualified medical personnel. To the one hand, what's the goal of all of that? Yes. So we added two physicians, Dr. Ciccieri and Dr. Gianetti at McGill University. We added Dr. Von Schwartz at UCLA, Dr. Galleri at the Boltzmann Institute. These are stem cell scientists who have done due diligence on Hemostemics and agree that this is going to be a first to patient approved therapeutic to treat heart disease and to treat critical limb ischemia amongst other diseases of ischemia. They're joining the board and the advisory board is a form of validation for you because Hemostemics passed their due diligence. Exactly right. So let's talk about the market for a bit. 75 million shares trading around, you know, you bounce between like 15 and 20 cents. Yes. Why? Yes. Well, there's a legacy issue there, Peter, which is one that you're well familiar with. We, you know, we did a rescue of this company. And the legacy issue is really the stocks trading on a legacy value. It hasn't really caught the imagination yet of the investing public. And what will make that happen? The I think the the announcements through 2023 are really milestone announcements that, you know, we've alluded to in the appointment of Dr. Gianetti and Ciccieri at McGill in the November announcement where we discussed, you know, they're coming on board to help us with financing introductions with due diligence responses with design of the fourth heart study with reestablishment of production at and so those are significant milestones and reaching any one of those it should be a should have a significant impact. You mentioned production. I find that interesting. Apart from proving up the technology, you want to get into your own production and be your own vertical supply chain. Exactly. So, you know, it's what the the stem cell industry, the reason it's gone to a donor stem cell focus in my view, just to keep it simple, is that you can take a donor cell and you can multiply it a thousand times and thereby theoretically have a product that can be used to treat a thousand people. In team of stemming case, we take your blood, we process your stem cells from your blood and we create a therapeutic that regenerates your heart or saves your limb. And that is viewed as a service business. We've figured out and patented and are working with suppliers to scale that so we can take that to 4,000 or more batches a month. And, you know, the numbers are very significant at $25,000 of treatment, $30,000 of treatment, you know, obviously the numbers get very large, very fast. And so but you have to prove to the world you can do it and we've got the Peter Pavlin has been our lead engineer on this, he's been working on this first in 2008 and now for over a year where we've gone out and looked at the whole industry and benchmarked our technology against the industry and we're very confident that we have a, you know, not only a very interesting technology in terms of ACP, a technology that works, which we think we've proven, but we're able to scale it. So with any forward-looking information, there's a disclosure of risks and interferences that could get in the way of that happening, but your goal is to be in production this year, it sounds like. That's right. We'll be in back in production this year and that for clinical trials and for compassionate care. Lots of news coming. Lots of news coming in 2023. This is, you know, last year was a turnaround year, this year is hit the pole and go. Well, you know, I'm a shareholder and a cheerleader, so I'll be watching closely. Let's do this again in a couple of months. That sounds like a great plan, Peter. Thank you. Hemostamix, HEM on the Venture Exchange. I'm Peter Clossey for Investor and Tell. Have a great day.